Cusp overlap technique decreases paravalvular leakage in self-expandable transcatheter aortic valve replacement. 2024

Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
Division of Cardiovascular Surgery, Department of Surgery, Kurume University School of Medicine, 67 Asahi-Machi, Kurume-Shi, Fukuoka, 830-0011, Japan. ttakaseya@kurume-u.ac.jp.

The cusp overlap technique allows greater visual separation between the basal annular plane and the conduction system and decreases the permanent pacemaker implantation rate. We assessed the impact of the cusp overlap technique on conduction disturbance and paravalvular leakage after transcatheter aortic valve replacement. A total of 97 patients underwent transfemoral transcatheter aortic valve replacement with self-expandable valves at our institution from November 2018 to January 2023. The mean age of the patients was 85 years, and 23% were male. The patients were divided into two groups: the cusp overlap technique group and the non-cusp overlap technique group. We compared the clinical results between the two groups. The 30-day permanent pacemaker implantation rate was similar between the two groups (cusp overlap technique: 6.3% vs. non-cusp overlap technique: 10.2%, p = 0.48). The rate of new-onset conduction disturbance was slightly lower in the cusp overlap than non-cusp overlap technique group (18.8% vs. 34.7%, respectively; p = 0.08). The implanted valve function was similar between the two groups, but the rate of trivial or less paravalvular leakage (PVL) was significantly higher in the cusp overlap technique group on echocardiography (69% vs. 45%, p = 0.02). On multidetector computed tomography, the implantation depth at the membranous septum was significantly shorter in the cusp overlap technique group (2.0 ± 2.3 vs. 2.9 ± 1.5 mm, p = 0.02). The degree of canting was slightly smaller in the cusp overlap technique group (1.0 ± 2.2 vs. 1.7 ± 1.9 mm, p = 0.07). The relative risk of PVL equal to or greater than mild was 1.76 times higher for valve implantation without the cusp overlap technique (adjusted odds ratio, 3.74; 95% confidence interval, 1.45-9.69; p < 0.01). Transcatheter aortic valve replacement using the cusp overlap technique is associated with an optimized implantation depth, leading to fewer conduction disturbances. Optimal deployment may also maximize the radial force of self-expanding valves to reduce paravalvular leakage.

UI MeSH Term Description Entries
D008297 Male Males
D011474 Prosthesis Design The plan and delineation of prostheses in general or a specific prosthesis. Design, Prosthesis,Designs, Prosthesis,Prosthesis Designs
D005260 Female Females
D006350 Heart Valve Prosthesis A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material. Prosthesis, Heart Valve,Cardiac Valve Prosthesis,Cardiac Valve Prostheses,Heart Valve Prostheses,Prostheses, Cardiac Valve,Prostheses, Heart Valve,Prosthesis, Cardiac Valve,Valve Prostheses, Cardiac,Valve Prostheses, Heart,Valve Prosthesis, Cardiac,Valve Prosthesis, Heart
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075224 Cardiac Conduction System Disease Diseases characterized by pathological irregularities in the HEART CONDUCTION SYSTEM. They may be associated with other heart diseases and syndromes (e.g., BRUGADA SYNDROME; NEUROMUSCULAR DISEASE, HEART BLOCKS), isolated or may result from injuries. You can have a conduction disorder without having an arrhythmia, but some arrhythmias arise from conduction disorders. OMIM: 601144. Cardiac Conduction Defect,Cardiac Conduction Defects,Cardiac Conduction System Diseases,Conduction Defect, Cardiac,Defect, Cardiac Conduction
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D001021 Aortic Valve The valve between the left ventricle and the ascending aorta which prevents backflow into the left ventricle. Aortic Valves,Valve, Aortic,Valves, Aortic
D001024 Aortic Valve Stenosis A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA. Aortic Stenosis,Aortic Valve Stenoses,Stenoses, Aortic,Stenoses, Aortic Valve,Stenosis, Aortic,Stenosis, Aortic Valve,Valve Stenoses, Aortic,Valve Stenosis, Aortic
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
December 2022, JACC. Cardiovascular interventions,
Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
January 2024, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,
Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
June 2021, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology,
Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
February 2024, European heart journal. Case reports,
Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
January 2022, Frontiers in physiology,
Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
March 2022, Journal of clinical medicine,
Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
August 2018, JACC. Cardiovascular interventions,
Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
March 2020, Acta Cardiologica Sinica,
Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
June 2015, The Journal of invasive cardiology,
Tohru Takaseya, and Naoki Itaya, and Ken-Ichiro Sasaki, and Masahiro Sasaki, and Michiko Yokomizo, and Akihiro Honda, and Kensuke Oshita, and Junpei Azuma, and Yoshihiro Fukumoto, and Eiki Tayama
April 2022, Cardiovascular intervention and therapeutics,
Copied contents to your clipboard!